Novo Nordisk A/S (BVMF:N1VO34)

Market Cap	943.46B -41.4%
Revenue (ttm)	267.62B +6.4%
Net Income	88.70B +1.4%
EPS	19.94 +1.8%
Shares Out	n/a
PE Ratio	10.64
Forward PE	12.89
Dividend	0.81 (3.16%)
Ex-Dividend Date	Mar 27, 2026

Volume	44,789
Average Volume	23,203
Open	25.93
Previous Close	25.39
Day's Range	25.85 - 26.66
52-Week Range	22.90 - 57.25
Beta	0.27
RSI	53.37
Earnings Date	May 6, 2026

About Novo Nordisk

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1923
• Employees: 69,150
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: N1VO34

Financial Performance

In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.

Financial numbers in DKK